百利天恒(688506.SH)：注射用iza-bren(EGFR×HER3双抗ADC)用于局部晚期或转移性尿路上皮癌患者纳入突破性治疗品种名单

Core Viewpoint - Baili Tianheng (688506.SH) has announced that its self-developed first-in-class and new concept drug, iza-bren (EGFR×HER3 dual antibody ADC), has been included in the list of breakthrough therapies by the National Medical Products Administration's Drug Evaluation Center for patients with unresectable locally advanced or metastatic urothelial carcinoma who have failed platinum-based chemotherapy and PD-1/PD-L1 inhibitors [1] Group 1 - The drug iza-bren is the only one to have entered Phase III clinical trials in its category [1] - The inclusion in the breakthrough therapy list signifies a potential acceleration in the drug's development and approval process [1] - The announcement highlights the company's commitment to innovative cancer treatments [1]